EP31670 / Epigenetix, adMare BioInnovations 
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
EP31670 / Epigenetix
NCT05488548: Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Recruiting
1
75
US
EP31670, NEO2734
Epigenetix, Inc.
Castrate Resistant Prostate Cancer, NUT Carcinoma, Chronic Myelomonocytic Leukemia, Myelofibrosis
05/25
05/25

Download Options